Overview

ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma

Status:
Withdrawn

Trial end date:
2018-02-24

Target enrollment:

Participant gender:

Summary

Neoadjuvant Vemurafenib and Cobimetinib in BRAF V600 Mutant Stage IIIB-C Melanoma • To evaluate the overall radiological complete response rate in patients with stage IIIB/C melanoma after 8 weeks of neoadjuvant vemurafenib and cobimetinib

Phase:

Phase 2

Details

Lead Sponsor:

Inova Health Care Services

Collaborator:

Genentech, Inc.

Treatments:

Vemurafenib